Gilead’s TROP-2 Trodelvy, Keytruda combo win first-line FDA nods for breast cancer

Gilead’s Trodelvy can now be used as a monotherapy and in combination with Merck’s Keytruda to treat certain patients with triple-negative breast cancer.